ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Geert R. D'Haens  ¹     Marla C. Dubinsky  ²     Laurent Peyrin-Biroulet  ^{3, 4}     Silvio Danese  ⁵     Bruce E. Sands  ⁵     Doug Wolf  ⁶     Andres Yarur  ⁷     Michael Chiorean  ⁸     Danielle Dray  ⁹     Irene Modesto  ¹⁰     Huaming Tan  ¹¹     Guibao Gu  ¹²     Claudia Lopez  ¹³     Chinyu Su  ¹⁴     Jinkun Zhang  ¹⁵     Fabio Cataldi  ¹⁵     Aoibhinn McDonnell  ¹⁶     Stefan Schreiber  ¹⁷     Brian G. Feagan  ^{18, 19}     Severine Vermeire  ^20    
1 Amsterdam University Medical Centres, Amsterdam, Netherlands
² Icahn School of Medicine at Mount Sinai, New York, United States
³ University of Lorraine, CHRU-Nancy, Nancy, France
⁴ University of Lorraine, Inserm, NGERE, Nancy, France
⁵ IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
⁶ Atlanta Gastroenterology Associates, Atlanta, United States
⁷ Cedars-Sinai Medical Center, Los Angeles, United States
⁸ Swedish Medical Center, Seattle, United States
⁹ Pfizer Inc, New York, United States
¹⁰ Pfizer Inc, Madrid, Spain
¹¹ Pfizer Inc, Groton, United States
¹² Pfizer Inc, San Diego, United States
¹³ Landos Biopharma, Blacksburg, United States
¹⁴ Pfizer Inc, Collegeville, United States
¹⁵ Arena Pharmaceuticals, San Diego, United States
¹⁶ Pfizer Ltd, Sandwich, United Kingdom
¹⁷ University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
¹⁸ Western University, London, Canada
¹⁹ Alimentiv Inc, London, Canada
²⁰ University Hospital Leuven, Leuven, Belgium

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)